Article: Roche releases Phase III results of Rituximab on Lymphoma

HopingSince88

Senior Member
Messages
335
Likes
10
Location
Maine
"Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III PRIMA study. The data showed that continuing MabThera (rituximab) for two years in patients who responded to initial treatment with MabThera plus chemotherapy, doubled the likelihood of them living without their disease worsening, known as progression-free survival (PFS), compared to those who did not receive maintenance."

Link:

http://www.roche.com/media/media_releases/med-cor-2010-05-21.htm